Cancer Supportive Care Products Market
Cancer Supportive Care Products Market By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Compounding Pharmacies) & Region - Forecast to 2020-2030
Market Insights on Cancer Supportive Care Products covering sales outlook, demand forecast and up-to-date key trends
Cancer Supportive Care Products Market Outlook & Key Findings
- Cancer supportive care products market is expected to grow at about 4% y-o-y in 2020
- Erythropoietin stimulating agents to hold leading revenue share, given their efficacy in treating chemotherapy-induced anemia
- Sales of cancer supportive care products via hospital pharmacies to remain prominent through 2030
- Usage of cancer supportive care products in treating leukemia to accelerate in the coming years
- North America to spearhead the global cancer supportive care products market over the following decade
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Cancer Supportive Care Products Market Analysis
Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.
While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.
Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.
In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.
Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.
The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020-2030.
Cancer Supportive Care Products Market Trends – The Biosimilar Solution to Expensive Cancer Treatment
Biosimilar drugs (or biosimilars), used in management of several disease conditions, account for about 25% of global pharmaceutical industry.
Adoption of biosimilar drugs among patients having cancer has triggered significant advancements in cancer treatments and supportive care.
The US FDA has approved various biosimilars for treatment of cancer and supportive care management, and the figure is expected to follow a positive trend.
Further, usage of biosimilars is associated with exponential cost-savings. Recent studies stress that biosimilars will result in a reduction of US$ 54 Bn in direct expenditure on biologic drugs over 2017-2026, or around 3% of overall anticipated biologic spending within the same timeframe, ranging of US $24-150 Bn.
Prominent drivers of cost savings include number and timing of biosimilars in development and marketing, acceptability of usage among prescribers and patients, cost of biosimilar development, changes in global market size, cost-sharing, payer coverage, and other regulatory policies.
Although these figures appear promising, the expected cost savings with usage of biosimilars are projected to remain modest.
Globally, the cost of biosimilars is about 20-30% less compared to that of reference drugs. The cost savings will bank on several factors such as cost of reference drugs, their sales, and degree of competition.
Hospital Pharmacies to Remain Leading Value Creator
Among the distribution channels, hospital pharmacies are expected to generate greater total return to shareholders (TRS) – over 50% of overall cancer supportive care products market revenue.
About 33% of overall healthcare companies are looking forward to transmuting their whole business model in 2020, with hospitals, the major providers of cancer care, accounting for 66% of them.
Pharmacy is an ever-evolving landscape, as such, hospital pharmacies are striving to keep pace with surging demand for cancer supportive care products and consistent rise in healthcare expenses. With inbound costs of oncology drugs, hospital pharmacies are in a constant juggle to reduce expenses and keep the budget on track.
Hospital pharmacies are monitoring trends on cancer supportive care products that have measurable effect on pharmacy budget in order to ensure maximum savings for hospitals’ pharmaceutical expenses.
While hospital pharmacies continue to capture a bigger slice of cancer supportive care products market value, players are also unlocking new revenue lines in retail pharmacies.
Cancer Supportive Care Products Market Regional Analysis – North America Leads, APAC’s Market to Speed up
Regionally, North America continues to engage manufacturers of cancer supportive care products over the following decade. Cancer is the major cause of mortality in Canada and the second-leading cause, after cardiovascular diseases (CVD), in the US.
- Around 1.9 million new incidences of cancer and 693,000 cancer mortalities were reported in Northern America in 2018.
- The most prevalently diagnosed cancers are prostate and breast cancer, while lung cancer remains the leading cause of mortality in the region.
Consequently, governments in the US and Canada are substantially investing in cancer research and development of pharmaceutical drugs, especially erythropoietin stimulating agents, and granulocyte colony stimulating factors.
Moreover, the regulatory authorities have been showing immediacy in approving various cancer supportive care products. The US has granted approval to around 23 biosimilars by July 2019, of which 14 carry indications for use in oncology.
In a similar vein, Asia Pacific (APAC) is also offering value-capture opportunities for players in of cancer supportive care products market.
Studies reveal that nearly half of the global cancer cases are reported in APAC, and by 2030, the number of individuals fighting cancer is likely to soar by about 35%, with mortality increasing by about 40%.
Biopharmaceutical companies in APAC are beginning to launch APAC-centric clinical therapeutics research. Within oncology domain, major portion of APAC drug development is centered on breast, lung, and colorectal cancers. Carrying an enormous cancer burden, the oncology drug market in China is expected to hit US$ 18 Bn by 2023.
Driven by expanding healthcare needs in tandem with supportive government policies. APAC represents tremendous opportunity for cancer supportive care product manufacturers. Countries are implementing steps to set up domestic environments that can leverage local talent and fetch foreign investment.
Cancer Supportive Care Products Market Players – Product Innovations and Launches to Shape Stakeholders’ Tactics
The cancer supportive care products market is witnessing the penetration of emerging players both at local and international level. The rising level of market competition is making new product launches, innovative applications, and tech-enabled developments a key priority among market players. Some of these include,
- Amgen Inc. develops and delivers innovative human therapeutics – Neulasta - a PEGylated form of human granulocyte CSF.
- Baxter International Inc. offers products under the business categories - Medication Delivery, Renal Care, and Pharmaceuticals. The company develops REGLAN Injection, which is a metoclopramide injection.
- Bayer AG works under several business segments - Crop science, Pharmaceuticals, Animal health, and Consumer health. The company develops Xarelto, which incorporates rivaroxaban.
- Daiichi Sankyo Co. Ltd. provides products under Pharmaceutical operation business unit. The company develops Naruvein Injection - a hydromorphone hydrochloride injection.
- GlaxoSmithKline Plc delivers products under business segments – Vaccines, Pharmaceuticals, and Consumer healthcare. The company develops REZONIC - a neurokinin 1 receptor antagonist.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cancer Supportive Care Products Market Future Outlook – Cannabis-based Products to Emerge as Potential Oncological Wonder
Recent medical studies are underway unleashing the potential of cannabis or cannabidiol (CBD) in cancer treatment. With limited number of opportunities for cancer treatment currently, CBD is likely to hold great promise for both patients and scientists in addressing the situation.
Given its cytotoxic, antiemetic, and anti-inflammatory effects, CBD has been garnering huge attention to its possible usage as a potent anti-cancer agent.
While regulatory bodies in the US have prohibited cannabis consumption, several states in the US, as well as some countries across the globe have legalized cannabis consumption for medical applications.
Two CBD drugs have been approved by the US Food and Drug Administration (FDA) - nabilone and dronabinol were researched as potent antiemetic medications.
Research and trials are in progress, incorporating swathes of scientists worldwide scrutinizing the potential of CBD for cancer treatment. However, these studies are yet to discover ample concrete scientific evidence to prove the safety and efficacy of CBD oil in treating cancer.
These scientific studies and research have been performed using animals or cancer cells developed in the laboratories. Human beings are more complex compared to animals, as such, results elaborated after the studies might not work as effectively for humans as they did in animal trials.
At present, the loopholes in research studies regarding consumption of CBD oil are creating hindrance for its approval as a potential medication for cancer treatment
Key Segment
Drug Class
- Nonsteroidal Anti- Inflammatory Drugs
- Anti-Infective
- Anti-Emetics
- Monoclonal Antibodies
- Erythropoietin Stimulating Agents
- Opioid Analgesics
- Bisphosphonates
- Granulocyte Colony Stimulating Factor
Indication
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Leukemia
- Ovarian Cancer
- Melanoma
- Others
Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Compounding Pharmacies
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Frequently Asked Questions
What is the Growth Outlook for Cancer Supportive Care Products Market?
The cancer supportive care products market is likely to secure a CAGR of 2.5% through 2032.
By 2032, how much can the Cancer Supportive Care Products Market Grow?
The cancer supportive care products market size is estimated to cross US$ 26.41 Bn by 2032.
What is the Current Valuation of the Cancer Supportive Care Products Market?
The cancer supportive care products market is likely to record a value of US$ 20.63 Bn in 2022.
Which Region is likely to Lead the Cancer Supportive Care Products Market?
North America is likely to lead the cancer supportive care products market.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Market Trends 3.2. Key Product/Development Trends 4. Key Success Factors 4.1. Parent Market Overview 4.2. PEST 4.3. Regulations 4.4. Key Promotional Strategies, By Key Manufacturers 5. Global Market Demand (in Volume) Analysis 2015-2019 and Forecast, 2020-2030 5.1. Historical Market Volume Analysis, 2015-2019 5.2. Current and Future Market Volume Projections, 2020-2030 5.3. Y-o-Y Growth Trend Analysis 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Drug Class 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2015–2019 and Forecast, 2020–2030 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019 7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Healthcare Expenditure Outlook 8.2. Forecast Factors - Relevance & Impact 8.2.1. Average Product Cost of Cancer Supportive Care Products 8.2.2. Frequency of Product Launches 8.2.3. Per Patient Spending 8.2.4. Product Awareness 8.2.5. Regulatory Approval Timeline 8.3. Value Chain 8.4. Market Dynamics 8.4.1. Drivers 8.4.2. Restraints 8.4.3. Opportunity Analysis 9. COVID19 Crisis Analysis 9.1. Current COVID19 Statistics and Probable Future Impact 9.2. Current GDP Projection and Probable Impact 9.3. Current Economic Projection as compared to 2008 Economic analysis 9.4. COVID19 and Impact Analysis 9.4.1. Revenue By Drug Class 9.4.2. Revenue By Country 9.5. 2020 Market Scenario 9.6. Quarter by Quarter Forecast 9.7. Projected recovery Quarter 9.8. Recovery Scenario – Short term, Midterm and Long Term Impact 10. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Drug Class , 2015 - 2019 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Drug Class, 2020 - 2030 10.3.1. Nonsteroidal Anti- Inflammatory Drugs 10.3.2. Anti-Infective 10.3.3. Anti-Emetics 10.3.4. Monoclonal Antibodies 10.3.5. Erythropoietin Stimulating Agents 10.3.6. Opioid Analgesics 10.3.7. Bisphosphonates 10.3.8. Granulocyte Colony Stimulating Factor 10.4. Market Attractiveness Analysis By Drug Class 11. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Indication 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2019 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 - 2030 11.3.1. Lung Cancer 11.3.2. Breast Cancer 11.3.3. Prostate Cancer 11.3.4. Liver Cancer 11.3.5. Bladder Cancer 11.3.6. Leukemia 11.3.7. Ovarian Cancer 11.3.8. Melanoma 11.3.9. Others 11.4. Market Attractiveness Analysis By Indication 12. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel , 2015 - 2019 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 - 2030 12.3.1. Hospital Pharmacies 12.3.2. Retail Pharmacies 12.3.3. Compounding Pharmacies 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Region 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2019 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2015-2019 and Forecast 2020-2030 14.1. Introduction 14.2. Regional Dynamics 14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 14.4.1. By Country 14.4.1.1. U.S. 14.4.1.2. Canada 14.4.2. By Drug Class 14.4.3. By Indication 14.4.4. By Distribution Channel 14.5. Market Attractiveness Analysis 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Latin America Market Analysis 2015-2019 and Forecast 2020-2030 15.1. Introduction 15.2. Regional Dynamics 15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 15.4.1. By Country 15.4.1.1. Brazil 15.4.1.2. Mexico 15.4.1.3. Rest of Latin America 15.4.2. By Drug Class 15.4.3. By Indication 15.4.4. By Distribution Channel 15.5. Market Attractiveness Analysis 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Europe Market Analysis 2015-2019 and Forecast 2020-2030 16.1. Introduction 16.2. Regional Dynamics 16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 16.4.1. By Country 16.4.1.1. Germany 16.4.1.2. Italy 16.4.1.3. France 16.4.1.4. U.K. 16.4.1.5. Spain 16.4.1.6. Russia 16.4.1.7. Rest of Europe 16.4.2. By Drug Class 16.4.3. By Indication 16.4.4. By Distribution Channel 16.5. Market Attractiveness Analysis 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. South Asia Market Analysis 2015-2019 and Forecast 2020-2030 17.1. Introduction 17.2. Regional Dynamics 17.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 17.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 17.4.1. By Country 17.4.1.1. India 17.4.1.2. Malaysia 17.4.1.3. Indonesia 17.4.1.4. Thailand 17.4.1.5. Rest of South Asia 17.4.2. By Drug Class 17.4.3. By Indication 17.4.4. By Distribution Channel 17.5. Market Attractiveness Analysis 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. East Asia Market Analysis 2015-2019 and Forecast 2020-2030 18.1. Introduction 18.2. Regional Dynamics 18.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 18.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 18.4.1. By Country 18.4.1.1. China 18.4.1.2. Japan 18.4.1.3. South Korea 18.4.2. By Drug Class 18.4.3. By Indication 18.4.4. By Distribution Channel 18.5. Market Attractiveness Analysis 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 19. Oceania Market Analysis 2015-2019 and Forecast 2020-2030 19.1. Introduction 19.2. Regional Dynamics 19.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 19.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 19.4.1. By Country 19.4.1.1. Australia 19.4.1.2. New Zealand 19.4.2. By Drug Class 19.4.3. By Indication 19.4.4. By Distribution Channel 19.5. Market Attractiveness Analysis 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 20. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020-2030 20.1. Introduction 20.2. Regional Dynamics 20.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 20.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 20.4.1. By Country 20.4.1.1. GCC Countries 20.4.1.2. South Africa 20.4.1.3. Rest of Middle East and Africa 20.4.2. By Drug Class 20.4.3. By Indication 20.4.4. By Distribution Channel 20.5. Market Attractiveness Analysis 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 21. Key and Emerging Countries Market Analysis 2015-2019 and Forecast 2020-2030 21.1. Introduction 21.1.1. Market Value Proportion Analysis, By Key Countries 21.1.2. Global Vs. Country Growth Comparison 21.2. U.S. Market Analysis 21.2.1. By Drug Class 21.2.2. By Indication 21.2.3. By Distribution Channel 21.3. Canada Market Analysis 21.3.1. By Drug Class 21.3.2. By Indication 21.3.3. By Distribution Channel 21.4. Mexico Market Analysis 21.4.1. By Drug Class 21.4.2. By Indication 21.4.3. By Distribution Channel 21.5. Brazil Market Analysis 21.5.1. By Drug Class 21.5.2. By Indication 21.5.3. By Distribution Channel 21.6. U.K. Market Analysis 21.6.1. By Drug Class 21.6.2. By Indication 21.6.3. By Distribution Channel 21.7. Germany Market Analysis 21.7.1. By Drug Class 21.7.2. By Indication 21.7.3. By Distribution Channel 21.8. France Market Analysis 21.8.1. By Drug Class 21.8.2. By Indication 21.8.3. By Distribution Channel 21.9. Italy Market Analysis 21.9.1. By Drug Class 21.9.2. By Indication 21.9.3. By Distribution Channel 21.10. Spain Market Analysis 21.10.1. By Drug Class 21.10.2. By Indication 21.10.3. By Distribution Channel 21.11. Russia Market Analysis 21.11.1. By Drug Class 21.11.2. By Indication 21.11.3. By Distribution Channel 21.12. China Market Analysis 21.12.1. By Drug Class 21.12.2. By Indication 21.12.3. By Distribution Channel 21.13. Japan Market Analysis 21.13.1. By Drug Class 21.13.2. By Indication 21.13.3. By Distribution Channel 21.14. South Korea Market Analysis 21.14.1. By Drug Class 21.14.2. By Indication 21.14.3. By Distribution Channel 21.15. India Market Analysis 21.15.1. By Drug Class 21.15.2. By Indication 21.15.3. By Distribution Channel 21.16. Thailand Market Analysis 21.16.1. By Drug Class 21.16.2. By Indication 21.16.3. By Distribution Channel 21.17. Indonesia Market Analysis 21.17.1. By Drug Class 21.17.2. By Indication 21.17.3. By Distribution Channel 21.18. Malaysia Market Analysis 21.18.1. By Drug Class 21.18.2. By Indication 21.18.3. By Distribution Channel 21.19. Australia Market Analysis 21.19.1. By Drug Class 21.19.2. By Indication 21.19.3. By Distribution Channel 21.20. New Zealand Market Analysis 21.20.1. By Drug Class 21.20.2. By Indication 21.20.3. By Distribution Channel 21.21. GCC Countries Market Analysis 21.21.1. By Drug Class 21.21.2. By Indication 21.21.3. By Distribution Channel 21.22. South Africa Market Analysis 21.22.1. By Drug Class 21.22.2. By Indication 21.22.3. By Distribution Channel 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies (Cancer Supportive Care Products) 22.2. Market Concentration 22.3. Market Share Analysis of Top Players 22.4. Market Presence Analysis 22.4.1. By Regional Footprint of Players 22.4.2. Product Footprint by Players 22.4.3. Channel Footprint by Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Pricing Analysis by Competition 23.3. Competition Benchmarking 23.4. Competition Deep Dive 23.4.1. Amgen, Inc. 23.4.1.1. Overview 23.4.1.2. Product Portfolio 23.4.1.3. Sales Footprint 23.4.1.4. Analyst commentary 23.4.2. Johnson & Johnson Private Limited 23.4.2.1. Overview 23.4.2.2. Product Portfolio 23.4.2.3. Sales Footprint 23.4.2.4. Analyst commentary 23.4.3. Baxter 23.4.3.1. Overview 23.4.3.2. Product Portfolio 23.4.3.3. Sales Footprint 23.4.3.4. Analyst commentary 23.4.4. Merck 23.4.4.1. Overview 23.4.4.2. Product Portfolio 23.4.4.3. Sales Footprint 23.4.4.4. Analyst commentary 23.4.5. Heron Pharma 23.4.5.1. Overview 23.4.5.2. Product Portfolio 23.4.5.3. Sales Footprint 23.4.5.4. Analyst commentary 23.4.6. Tesaro 23.4.6.1. Overview 23.4.6.2. Product Portfolio 23.4.6.3. Sales Footprint 23.4.6.4. Analyst commentary 23.4.7. Enlivity Corporation 23.4.7.1. Overview 23.4.7.2. Product Portfolio 23.4.7.3. Sales Footprint 23.4.7.4. Analyst commentary 23.4.8. AmerisourceBergen Corporation (ASD Healthcare) 23.4.8.1. Overview 23.4.8.2. Product Portfolio 23.4.8.3. Sales Footprint 23.4.8.4. Analyst commentary 23.4.9. Veru, Inc. 23.4.9.1. Overview 23.4.9.2. Product Portfolio 23.4.9.3. Sales Footprint 23.4.9.4. Analyst commentary 23.4.10. ARIAD Pharmaceuticals, Inc. 23.4.10.1. Overview 23.4.10.2. Product Portfolio 23.4.10.3. Sales Footprint 23.4.10.4. Analyst commentary 23.4.11. Bendalis GmbH 23.4.11.1. Overview 23.4.11.2. Product Portfolio 23.4.11.3. Sales Footprint 23.4.11.4. Analyst commentary 23.4.12. Helsinn Healthcare 23.4.12.1. Overview 23.4.12.2. Product Portfolio 23.4.12.3. Sales Footprint 23.4.12.4. Analyst commentary 23.4.13. Novartis AG 23.4.13.1. Overview 23.4.13.2. Product Portfolio 23.4.13.3. Sales Footprint 23.4.13.4. Analyst commentary 23.4.14. Hoffmann-La Roche Ltd 23.4.14.1. Overview 23.4.14.2. Product Portfolio 23.4.14.3. Sales Footprint 23.4.14.4. Analyst commentary 23.4.15. Fagron 23.4.15.1. Overview 23.4.15.2. Product Portfolio 23.4.15.3. Sales Footprint 23.4.15.4. Analyst commentary 23.4.16. Teva Pharmaceutical Industries Ltd. 23.4.16.1. Overview 23.4.16.2. Product Portfolio 23.4.16.3. Sales Footprint 23.4.16.4. Analyst commentary 24. Assumptions and Acronyms Used 25. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Value By Drug Classes, 2020–2030(US$ Mn) Table 02: Global Market Value By Disease Indication, 2020–2030(US$ Mn) Table 03: Global Market Value By Distribution Channel, 2020–2030(US$ Mn) Table 04: North America Market Value By Drug Classes, 2020–2030(US$ Mn) Table 05: North America Market Value By Disease Indication, 2020–2030(US$ Mn) Table 06: North America Market Value By Distribution Channel, 2020–2030(US$ Mn) Table 07: Latin America Market Value By Drug Classes, 2020–2030(US$ Mn) Table 08: Latin America Market Value By Disease Indication, 2020–2030(US$ Mn) Table 09: Latin America Market Value By Distribution Channel, 2020–2030(US$ Mn) Table 10: Europe Market Value By Drug Classes, 2020–2030(US$ Mn) Table 11: Europe Market Value By Disease Indication, 2020–2030(US$ Mn) Table 12: Europe Market Value By Distribution Channel, 2020–2030(US$ Mn) Table 13: APAC Market Value By Drug Classes, 2020–2030(US$ Mn) Table 14: APAC Market Value By Disease Indication, 2020–2030(US$ Mn) Table 15: APAC Market Value By Distribution Channel, 2020–2030(US$ Mn) Table 16: MEA Market Value By Drug Classes, 2020–2030(US$ Mn) Table 17: MEA Market Value By Disease Indication, 2020–2030(US$ Mn) Table 18: MEA Market Value By Distribution Channel, 2020–2030(US$ Mn)
List of Charts
Figure 01: Global Oncology Drug Market Value (US$ Mn) 2020–2030 Figure 02: Global Cancer Supportive Care Drug Market – Scenario Forecast, 2020–2030(US$ Mn) Figure 03: Global Market Value & Y-o-Y Growth (%), 2020–2030 Figure 04: Global Market Absolute $ Opportunity, 2020–2030 Figure 05: Global Market Y-o-Y Growth Comparison By Drug Classes, 2020–2030 Figure 06: Market Value Share & BPS Analysis By Drug Classes, 2020 & 2030 Figure 07: Global Market Value & Y-o-Y Growth (%) By Nonsteroidal Anti-inflammatory Drugs, 2020–2030 Figure 08: Global Market Absolute $ Opportunity By Nonsteroidal Anti-inflammatory Drugs, 2020–2030 Figure 09: Global Market Value & Y-o-Y Growth (%) By Anti-infective, 2020–2030 Figure 10: Global Market Absolute $ Opportunity By Anti-infective, 2020–2030 Figure 11: Global Market Value & Y-o-Y Growth (%) By Anti-emetics, 2020–2030 Figure 12: Global Market Absolute $ Opportunity By Anti-emetics, 2020–2030 Figure 13: Global Market Value & Y-o-Y Growth (%) Monoclonal Antibodies, 2020–2030 Figure 14: Global Market Absolute $ Opportunity By Monoclonal Antibodies, 2020–2030 Figure 15: Global Market Value & Y-o-Y Growth (%) By Erythropoietin Stimulating Agents, 2020–2030 Figure 16: Global Market Absolute $ Opportunity By Erythropoietin Stimulating Agents, 2020–2030 Figure 17: Global Market Value & Y-o-Y Growth (%) By Opioid Analgesics, 2020–2030 Figure 18: Global Market Absolute $ Opportunity By Opioid Analgesics, 2020–2030 Figure 19: Global Market Value & Y-o-Y Growth (%) By Bisphosphonates, 2020–2030 Figure 20: Global Market Absolute $ Opportunity By Bisphosphonates, 2020–2030 Figure 21: Global Market Value & Y-o-Y Growth (%) By Granulocyte Colony Stimulating Factor, 2020–2030 Figure 22: Global Market Absolute $ Opportunity By Granulocyte Colony Stimulating Factor, 2020–2030 Figure 23: Global Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 24: Global Market Attractiveness Analysis By Indication, 2020–2030 Figure 25: Global Market Y-o-Y Growth Comparison By Indication, 2020–2030 Figure 26: Market Value Share & BPS Analysis By Indication, 2020 & 2030 Figure 27: Global Market Value & Y-o-Y Growth (%) By Lung Cancer, 2020–2030 Figure 28: Global Market Absolute $ Opportunity By Lung Cancer, 2020–2030 Figure 29: Global Market Value & Y-o-Y Growth (%) By Breast Cancer, 2020–2030 Figure 30: Global Market Absolute $ Opportunity By Breast Cancer, 2020–2030 Figure 31: Global Market Value & Y-o-Y Growth (%) By Prostate Cancer, 2020–2030 Figure 32: Global Market Absolute $ Opportunity By Prostate Cancer, 2020–2030 Figure 33: Global Market Value & Y-o-Y Growth (%) By Liver Cancer, 2020–2030 Figure 34: Global Market Absolute $ Opportunity By Liver Cancer, 2020–2030 Figure 35: Global Market Value & Y-o-Y Growth (%) By Bladder Cancer, 2020–2030 Figure 36: Global Market Absolute $ Opportunity By Bladder Cancer, 2020–2030 Figure 37: Global Market Value & Y-o-Y Growth (%) By Leukemia, 2020–2030 Figure 38: Global Market Absolute $ Opportunity By Leukemia, 2020–2030 Figure 39: Global Market Value & Y-o-Y Growth (%) By Ovarian Cancer, 2020–2030 Figure 40: Global Market Absolute $ Opportunity By Ovarian Cancer, 2020–2030 Figure 41: Global Market Value & Y-o-Y Growth (%) By Melanoma, 2020–2030 Figure 42: Global Market Absolute $ Opportunity By Melanoma, 2020–2030 Figure 43: Global Market Value & Y-o-Y Growth (%) By Other Cancer, 2020–2030 Figure 44: Global Market Absolute $ Opportunity By Other Cancer 2020–2030 Figure 45: Global Market Y-o-Y Growth Comparison By Distribution Channel, 2020–2030 Figure 46: Market Value Share & BPS Analysis By Distribution Channel, 2020 & 2030 Figure 47: Global Market Value & Y-o-Y Growth (%) By Hospital Pharmacies, 2020–2030 Figure 48: Global Market Absolute $ Opportunity By Hospital Pharmacies, 2020–2030 Figure 49: Global Market Value & Y-o-Y Growth (%) By Retail Pharmacies, 2020–2030 Figure 50: Global Market Absolute $ Opportunity By Retail Pharmacies, 2020–2030 Figure 51: Global Market Value & Y-o-Y Growth (%) By Compounding Pharmacies, 2020–2030 Figure 52: Global Market Absolute $ Opportunity By Compounding Pharmacies, 2020–2030 Figure 53: Global Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 54: Market Y-o-Y Growth Comparison By Region, 2020–2030 Figure 55: Market Value Share & BPS Analysis By Region, 2020 & 2030 Figure 56: Global Market Value & Y-o-Y Growth (%) for North America Region, 2020–2030 Figure 57: Global Market Absolute $ Opportunity for North America Region, 2020–2030 Figure 58: Global Market Value & Y-o-Y Growth (%) for Latin America Region, 2020–2030 Figure 59: Global Market Absolute $ Opportunity for Latin America Region, 2020–2030 Figure 60: Global Market Value & Y-o-Y Growth (%) for Europe Region, 2020–2030 Figure 61: Global Market Absolute $ Opportunity for Europe Region, 2020–2030 Figure 62: Global Market Value & Y-o-Y Growth (%) for Asia Pacific Region, 2020–2030 Figure 63: Global Market Absolute $ Opportunity for Asia Pacific Region, 2020–2030 Figure 64: Global Market Value & Y-o-Y Growth (%) for Middle East and Africa Region, 2020–2030 Figure 65: Global Market Absolute $ Opportunity for Middle East and Africa Region, 2020–2030 Figure 66: Global Market Attractiveness Analysis By Region, 2020–2030 Figure 67: U.S. Market Value & Y-o-Y Growth (%), 2020–2030 Figure 68: U.S. Market Absolute $ Opportunity, 2020–2030 Figure 69: Canada Market Value & Y-o-Y Growth (%), 2020–2030 Figure 70: Canada Market Absolute $ Opportunity, 2020–2030 Figure 71: North America Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 72: North America Market Attractiveness Analysis By Indication, 2020–2030 Figure 73: North America Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 74: North America Market Attractiveness Analysis By Country, 2020–2030 Figure 75: Argentina Market Value & Y-o-Y Growth (%) , 2020–2030 Figure 76: Argentina Market Absolute $ Opportunity, 2020–2030 Figure 77: Brazil Market Value & Y-o-Y Growth (%), 2020–2030 Figure 78: Brazil Market Absolute $ Opportunity, 2020–2030 Figure 79: Mexico Market Value & Y-o-Y Growth (%), 2020–2030 Figure 80: Mexico Market Absolute $ Opportunity, 2020–2030 Figure 81: Rest Of Latin America Market Value & Y-o-Y Growth (%), 2020–2030 Figure 82: Rest Of Latin America Market Absolute $ Opportunity, 2020–2030 Figure 83: Latin America Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 84: Latin America Market Attractiveness Analysis By Indication, 2020–2030 Figure 85: Latin America Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 86: Latin America Market Attractiveness Analysis By Country, 2020–2030 Figure 87: Germany Market Value & Y-o-Y Growth (%) , 2020–2030 Figure 88: Germany Market Absolute $ Opportunity, 2020–2030 Figure 89: U.K. Market Value & Y-o-Y Growth (%), 2020–2030 Figure 90: U.K. Market Absolute $ Opportunity, 2020–2030 Figure 91: France Market Value & Y-o-Y Growth (%), 2020–2030 Figure 92: France Market Absolute $ Opportunity, 2020–2030 Figure 93: Italy Market Value & Y-o-Y Growth (%), 2020–2030 Figure 94: Italy Market Absolute $ Opportunity, 2020–2030 Figure 95: Spain Market Value & Y-o-Y Growth (%), 2020–2030 Figure 96: Spain Market Absolute $ Opportunity, 2020–2030 Figure 97: Nordic Market Value & Y-o-Y Growth (%), 2020–2030 Figure 98: Nordic Market Absolute $ Opportunity, 2020–2030 Figure 99: Russia Market Value & Y-o-Y Growth (%), 2020–2030 Figure 100: Russia Market Absolute $ Opportunity, 2020–2030 Figure 101: Rest Of Europe Market Value & Y-o-Y Growth (%), 2020–2030 Figure 102: Rest Of Europe Market Absolute $ Opportunity, 2020–2030 Figure 103: Europe Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 104: Europe Market Attractiveness Analysis By Indication, 2020–2030 Figure 105: Europe Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 106: Europe Market Attractiveness Analysis By Country, 2020–2030 Figure 107: Greater China Market Value & Y-o-Y Growth (%), 2020–2030 Figure 108: Greater China Market Absolute $ Opportunity, 2020–2030 Figure 109: India Market Value & Y-o-Y Growth (%), 2020–2030 Figure 110: India Market Absolute $ Opportunity, 2020–2030 Figure 111: Japan Market Value & Y-o-Y Growth (%), 2020–2030 Figure 112: Japan Market Absolute $ Opportunity, 2020–2030 Figure 113: Australia and New Zealand Market Value & Y-o-Y Growth (%), 2020–2030 Figure 114: Australia and New Zealand Market Absolute $ Opportunity, 2020–2030 Figure 115: Rest of APAC Market Value & Y-o-Y Growth (%), 2020–2030 Figure 116: Rest of APAC Market Absolute $ Opportunity, 2020–2030 Figure 117: APAC Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 118: APAC Market Attractiveness Analysis By Indication, 2020–2030 Figure 119: APAC Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 120: APAC Market Attractiveness Analysis By Country, 2020–2030 Figure 121: GCC Market Value & Y-o-Y Growth (%), 2020–2030 Figure 122: GCC America Market Absolute $ Opportunity, 2020–2030 Figure 123: South Africa Market Value & Y-o-Y Growth (%), 2020–2030 Figure 124: South Africa Market Absolute $ Opportunity, 2020–2030 Figure 125: Rest Of MEA Market Value & Y-o-Y Growth (%), 2020–2030 Figure 126: Rest Of MEA Market Absolute $ Opportunity, 2020–2030 Figure 127: MEA Market Attractiveness Analysis By Drug Classes, 2020–2030 Figure 128: MEA Market Attractiveness Analysis By Indication, 2020–2030 Figure 129: MEA Market Attractiveness Analysis By Distribution Channel, 2020–2030 Figure 130: MEA Market Attractiveness Analysis By Country, 2020–2030
Recommendations
Explore Healthcare Insights
View Reports